Letter: Long-term use of proton pump inhibitors and risk of neuroendocrine tumours

Alimentary Pharmacology and Therapeutics

Volumn 43, Issue 6, 2016, Pages 749-

  Ezekwudo, D ^a   Tobi, M ^b  

^a Children's Hospital of Michigan   (United States)

^b Saginaw Steering Systems   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GASTRIN; PANTOPRAZOLE; PROTON PUMP INHIBITOR;

CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER RISK; CARCINOGENICITY; CELL GROWTH; CELL LINE; DRUG EFFECT; DRUG USE; ENTEROCHROMAFFIN LIKE CELL; GASTRIC NEUROENDOCRINE TUMOR; HUMAN; LETTER; NEUROENDOCRINE TUMOR; NIH 716 CELL LINE; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT DURATION; TROPHIC LEVEL; TUMOR CLASSIFICATION; FEMALE; MALE; STOMACH NEOPLASMS;

FEMALE; HUMANS; MALE; PROTON PUMP INHIBITORS; STOMACH NEOPLASMS;

EID: 84958568067     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13529     Document Type: Letter

References (10)

1. Schneider JL, Kolitsopoulos F, Corley DA,. Risk of gastric cancer, gastrointestinal cancers and other cancers: a comparison of treatment with pantoprazole and other proton pump inhibitors. Aliment Pharmacol Ther 2016; 43: 73-82.
2. Lamberts R, Creutzfeldt W, Stockmann F, Jacubaschke U, Maas S, Brunner G,. Long term omeprazole treatment in man: effects on gastric endocrine cell populations. Digestion 1998; 39: 126-35.
3. Klinkenberg-Knol EC, Festen HP, Jansen JB, et al,. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med 1994; 121: 161-7.
4. Bardram L, Stage JG, Stadil F,. Omeprazole treatment in the Zollinger-Ellison syndrome. Ugeskr Laeger 1985; 147: 867-9.
5. Tobi M, Chintalapani S, Goo R, et al,. Omeprazole inhibits growth of cancer cell line of colonic origin. Dig Dis Sci 1995; 40: 1526-30.
6. Gillen D, McColl KE,. Problems associated with the clinical use of proton pump inhibitors. Pharmacol Toxicol 2001; 89: 281-6.
7. Cavalcoli F, Zilli A, Conte D, Ciafardini C, Massironi S,. Gastric neuroendocrine neoplasms and proton pump inhibitors: fact or coincidence? Scand J Gastroenterol 2015; 50: 1397-403.
8. Tobi M, Cats A, Maliakkal B, et al,. Zollinger-Ellison syndrome, acromegaly and colorectal neoplasia. J Clin Gastroenterol 1997; 24: 21-4.
9. Boyce M, Thomsen L,. Gastric neuroendocrine tumors: prevalence in Europe, USA, and Japan, and rationale for treatment with a gastrin/CCK2 receptor antagonist. Scand J Gastroenterol 2015; 50: 550-9.
10. Wang BY, Zhang J,. Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancer. J Exp Clin Cancer Res 2015; 22: 34-85.